Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus

Endometrial Adenocarcinoma Clinical Trial

Official title:
A Phase III Randomized Clinical Trial of Laparoscopic Pelvic and Para-Aortic Node Sampling With Vaginal Hysterectomy and BSO Versus Open Laparotomy With Pelvic and Para-Aortic Node Sampling and Abdominal Hysterectomy and BSO in Endometrial Adenocarcinoma and Uterine Sarcoma, Clinical Stage I, IIA, Grade I, II, III

Status Completed

Clinical Trial Summary

This randomized phase III trial is studying laparoscopic surgery to see how well it works compared to standard surgery in treating patients with endometrial cancer or cancer of the uterus. Laparoscopic surgery is a less invasive type of surgery for cancer of the uterus and may have fewer side effects and improve recovery. It is not known whether laparoscopic surgery is more effective than standard surgery in treating endometrial cancer.

Clinical Trial Description

OBJECTIVES:

I. Compare the incidence of surgical complications, peri-operative morbidity, and mortality in patients with stage I or IIa, grade I-III endometrial cancer or uterine cancer undergoing surgical staging through laparoscopic assisted vaginal hysterectomy vs total abdominal hysterectomy.

II. Compare the length of hospital stay after surgery in patients receiving these treatments.

III. Compare the quality of life of patients receiving these treatments. IV. Compare the incidence and location of disease recurrence in patients receiving these treatments.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients undergo vaginal hysterectomy and bilateral salpingo-oophorectomy (BSO) via laparoscopy.

ARM II: Patients undergo total abdominal hysterectomy and BSO via conventional laparotomy.

Patients in both arms also undergo pelvic and para-aortic lymph node sampling. Quality of life is assessed at baseline, at 1, 3, and 6 weeks, and then at 6 months.

Patients are followed at 6 weeks, every 3 months for 2 years, and then every 6 months for 3 years. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00002706
Study type	Interventional
Source	Gynecologic Oncology Group
Contact
Status	Completed
Phase	Phase 3
Start date	April 1996

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01935973` - Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 1
Active, not recruiting	`NCT03660826` - Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone	Phase 2
Active, not recruiting	`NCT04106414` - Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment	Phase 2
Completed	`NCT01642082` - Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Completed	`NCT01208467` - Prognostic Biomarkers in Patients With Endometrial Cancer	N/A
Completed	`NCT01011933` - Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Completed	`NCT00025467` - Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Completed	`NCT01440998` - Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer	Phase 1
Completed	`NCT00006089` - Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer	Phase 2
Active, not recruiting	`NCT00977574` - Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer	Phase 2
Recruiting	`NCT05001282` - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)	Phase 1/Phase 2
Completed	`NCT01968317` - Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma	Phase 2
Completed	`NCT01225887` - Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Completed	`NCT01005329` - Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer	Phase 2
Active, not recruiting	`NCT02208375` - mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian	Phase 1/Phase 2
Completed	`NCT03716414` - Evaluation of the Efficacy for Sentinel Lymph Node Policy in High-risk Endometrial Carcinoma
Withdrawn	`NCT03836157` - Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer	Phase 2
Not yet recruiting	`NCT06399757` - A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors	Phase 1/Phase 2
Completed	`NCT00095979` - Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Completed	`NCT00072176` - Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer	Phase 2